Therma Bright Secures Major Distribution Deals in Growing Compression Therapy Market

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) has secured substantial distribution agreements and achieved unprecedented Medicare reimbursement approvals for its Venowave VW5 compression device, positioning the company for significant market expansion in the rapidly growing compression therapy sector.

The company's FDA-cleared Venowave VW5 device received Medicare and Medicaid HCPCS Level II code reimbursements in just 60 days, an unusually quick turnaround that demonstrates strong market acceptance. This development is particularly significant as the global compression therapy market is projected to grow from $4.18 billion in 2024 to $6.72 billion by 2033.

A major distribution agreement with Nashville-based DME Authority includes commitments for $6 million worth of Venowave VW5 units in the first half of 2025, with similar projections for the second half of the year. The distributor has already confirmed a purchase order of 1,750 units, representing potential reimbursements of $1.43 million USD.

The Venowave VW5's unique position as the only Medicare-approved mobile mechanical compression system under its code category could significantly impact patient care. The device increases venous blood flow by up to 88% while allowing patients to remain mobile during treatment, addressing a critical gap in the current market for portable compression therapy solutions.

This market expansion comes at a crucial time as healthcare systems worldwide seek cost-effective, non-invasive treatment options for an aging population. The rapid reimbursement approval and substantial distribution commitments suggest Therma Bright could capture a significant share of the growing compression therapy market, potentially transforming access to mobile compression therapy for Medicare patients.